S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Insiders Say New “Parallel Economy” Is Wave Of Future (Ad)pixel
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Insiders Say New “Parallel Economy” Is Wave Of Future (Ad)pixel
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Insiders Say New “Parallel Economy” Is Wave Of Future (Ad)pixel
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Insiders Say New “Parallel Economy” Is Wave Of Future (Ad)pixel
NASDAQ:GRTS

Gritstone bio - GRTS Stock Forecast, Price & News

$3.40
-0.07 (-2.02%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.38
$3.62
50-Day Range
$2.06
$3.47
52-Week Range
$1.71
$14.42
Volume
1.01 million shs
Average Volume
1.41 million shs
Market Capitalization
$247.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Gritstone bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
252.9% Upside
$12.00 Price Target
Short Interest
Healthy
3.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.15mentions of Gritstone bio in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.51) to ($1.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

253rd out of 1,108 stocks

Biological Products, Except Diagnostic Industry

40th out of 175 stocks

GRTS stock logo

About Gritstone bio (NASDAQ:GRTS) Stock

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Gritstone bio Stock Down 2.0 %

NASDAQ:GRTS traded down $0.07 on Wednesday, hitting $3.40. The stock had a trading volume of 1,005,445 shares, compared to its average volume of 1,412,542. Gritstone bio has a one year low of $1.71 and a one year high of $14.42. The stock has a market cap of $247.56 million, a price-to-earnings ratio of -2.43 and a beta of 0.51. The company's 50-day moving average is $2.56 and its two-hundred day moving average is $3.45.

Gritstone bio (NASDAQ:GRTS - Get Rating) last posted its earnings results on Thursday, August 4th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06. Gritstone bio had a negative net margin of 634.23% and a negative return on equity of 59.91%. During the same period in the previous year, the business posted ($0.33) earnings per share. On average, sell-side analysts anticipate that Gritstone bio will post -1.51 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price objective on shares of Gritstone bio from $15.00 to $12.00 in a research report on Monday, May 9th.

Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

GRTS Stock News Headlines

Gritstone Bio's Earnings Outlook
GRTS, ORIC and URGN among after hour movers
Gritstone bio files for $250M mixed shelf offering
See More Headlines
Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

GRTS Company Calendar

Last Earnings
8/04/2022
Today
8/10/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRTS
Fax
N/A
Employees
193
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+252.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-75,080,000.00
Net Margins
-634.23%
Pretax Margin
-634.23%

Debt

Sales & Book Value

Annual Sales
$48.21 million
Book Value
$3.18 per share

Miscellaneous

Free Float
69,558,000
Market Cap
$247.56 million
Optionable
Not Optionable
Beta
0.51

Key Executives

  • Dr. Andrew R. Allen BCh (Age 55)
    BM, M.D., MA, MRCP, Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $904.66k
  • Mr. Erin E. Jones M.S. (Age 50)
    Chief Operating Officer
    Comp: $597.74k
  • Dr. Karin Jooss Ph.D. (Age 57)
    Head of R&D
    Comp: $658.03k
  • Ms. Vassiliki Economides (Age 41)
    Exec. VP & CFO
  • Mr. James Cho
    Chief Accounting Officer
  • Mr. Rahsaan W. Thompson J.D. (Age 51)
    Exec. VP & Gen. Counsel
  • Ms. Stacy Proctor
    Sr. VP & Head of People
  • Dr. Matthew Hawryluk (Age 44)
    Exec. VP & Chief Bus. Officer
  • Mr. Vijay Yabannavar Ph.D. (Age 60)
    Exec. VP & Chief Technical Devel. Officer













GRTS Stock - Frequently Asked Questions

Should I buy or sell Gritstone bio stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GRTS shares.
View GRTS analyst ratings
or view top-rated stocks.

What is Gritstone bio's stock price forecast for 2022?

1 brokerages have issued 1-year target prices for Gritstone bio's shares. Their GRTS share price forecasts range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next year. This suggests a possible upside of 244.8% from the stock's current price.
View analysts price targets for GRTS
or view top-rated stocks among Wall Street analysts.

How have GRTS shares performed in 2022?

Gritstone bio's stock was trading at $12.86 at the start of the year. Since then, GRTS stock has decreased by 72.9% and is now trading at $3.48.
View the best growth stocks for 2022 here
.

When is Gritstone bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our GRTS earnings forecast
.

How were Gritstone bio's earnings last quarter?

Gritstone bio, Inc. (NASDAQ:GRTS) issued its earnings results on Thursday, August, 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.06. Gritstone bio had a negative trailing twelve-month return on equity of 59.91% and a negative net margin of 634.23%. During the same quarter in the previous year, the business earned ($0.33) EPS.

What is Andrew Allen's approval rating as Gritstone bio's CEO?

1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gritstone bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).

When did Gritstone bio IPO?

(GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

What is Gritstone bio's stock symbol?

Gritstone bio trades on the NASDAQ under the ticker symbol "GRTS."

Who are Gritstone bio's major shareholders?

Gritstone bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.36%), SkyOak Wealth LLC (0.18%), Russell Investments Group Ltd. (0.09%), Connor Clark & Lunn Investment Management Ltd. (0.02%), Institute for Wealth Management LLC. (0.02%) and Key Client Fiduciary Advisors LLC (0.01%). Insiders that own company stock include Erin Jones and Raphael Rousseau.
View institutional ownership trends
.

How do I buy shares of Gritstone bio?

Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gritstone bio's stock price today?

One share of GRTS stock can currently be purchased for approximately $3.48.

How much money does Gritstone bio make?

Gritstone bio (NASDAQ:GRTS) has a market capitalization of $253.39 million and generates $48.21 million in revenue each year. The company earns $-75,080,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How many employees does Gritstone bio have?

The company employs 193 workers across the globe.

How can I contact Gritstone bio?

Gritstone bio's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The official website for the company is www.gritstoneoncology.com. The company can be reached via phone at (510) 871-6100 or via email at ir@gritstone.com.

This page (NASDAQ:GRTS) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.